Trevi Therapeutics (TRVI) Accounts Payables (2018 - 2026)

Trevi Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 55.88% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 55.88% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 14.56% from the prior year.
• Accounts Payables eased to $2.2 million in Q1 2026 per TRVI's latest filing, from $3.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $3.9 million in Q2 2022 and bottomed at $1.3 million in Q3 2023.
• The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $2.3 million.
• Across the five-year window, Accounts Payables jumped 116.98% in 2022 and plunged 65.67% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $2.9 million in 2022, then plunged by 36.68% to $1.8 million in 2023, then jumped by 88.72% to $3.4 million in 2024, then advanced by 14.56% to $3.9 million in 2025, then slumped by 43.36% to $2.2 million in 2026.
• Per Business Quant, the three latest TRVI Accounts Payables figures stand at $2.2 million (Q1 2026), $3.9 million (Q4 2025), and $2.7 million (Q3 2025).